Iovance Biotherapeutics is a global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapy for cancer. The company is committed to a collaborative, inclusive environment and has demonstrated promising clinical data across multiple solid tumors.
Develop strategic direction for scientific marketing and medical education supporting AMTAGVI, the first FDA-approved T cell therapy for metastatic melanoma.
Lead national and regional peer-to-peer programming, including speaker programs and advisory boards, to drive impactful education and promotion.
Partner with Medical Affairs on publications, scientific communications, and real-world evidence generation while ensuring regulatory compliance.